Literature DB >> 31356530

Resolution of Symptoms and Resumption of Sex After Diagnosis of Nongonococcal Urethritis Among Men Who Have Sex With Men.

Laura C Chambers1, James P Hughes2, Sara N Glick3,4, Jennifer L Morgan3, M Sylvan Lowens3, Tashina S Robinson1, Sarah S Romano1, Gina L Leipertz1, Jørgen S Jensen5, Christine M Khosropour1, David N Fredricks4,6,7, Matthew R Golden1,3,4, Lisa E Manhart1,8.   

Abstract

BACKGROUND: Standard counseling at nongonococcal urethritis (NGU) diagnosis includes advice to abstain from sex for at least 7 days and until symptoms resolve.
METHODS: From December 2014 to July 2018, we enrolled men who have sex with men and received azithromycin (1 g) for NGU at the Public Health-Seattle and King County STD Clinic. Over 12 weeks of follow-up, participants reported daily urethral symptoms and sexual activity on web-based diaries. Nongonococcal urethritis was defined as urethral symptoms or visible urethral discharge plus 5 or greater polymorphonuclear leukocytes per high-power field. Time of symptom resolution was defined as the first of 5 consecutive asymptomatic days.
RESULTS: Of 100 participants with NGU and no Chlamydia trachomatis (CT)/Mycoplasma genitalium (MG) coinfection, 36 (36%), 22 (22%), and 42 (42%) had CT-NGU, MG-NGU, and non-CT/non-MG NGU, respectively. Among men with MG-NGU, 94% had a macrolide resistance mutation. For all etiologies, median time to symptom resolution after azithromycin was 7 days (95% confidence interval [CI], 5-9); 37% had symptoms lasting longer than 7 days. For men with CT-NGU, MG-NGU, and non-CT/non-MG NGU, median time to symptom resolution was 4 days (95% CI, 2-6; 16% >7 days), undefined days (95% CI, 7 to undefined; 60% >7 days), and 7 days (95% CI, 5-11; 46% >7 days), respectively. Median time to first sexual activity (any type) was 12 days (95% CI, 11-17); it was 16 days (95% CI, 12-18) to first urethral sexual exposure. Twenty-seven percent did not avoid urethral exposure for the recommended period.
CONCLUSIONS: Counseling at NGU diagnosis should educate patients that symptoms may persist more than 7 days, particularly for non-CT NGU, and emphasize the rationale for the 7-day abstinence period.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31356530      PMCID: PMC7008972          DOI: 10.1097/OLQ.0000000000001040

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  20 in total

1.  Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.

Authors:  J R Schwebke; A Rompalo; S Taylor; A C Seña; D H Martin; L M Lopez; S Lensing; J Y Lee
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection.

Authors:  Cybèle A Renault; Dennis M Israelski; Vivian Levy; Bruce K Fujikawa; Timothy A Kellogg; Jeffrey D Klausner
Journal:  Sex Health       Date:  2011-03       Impact factor: 2.706

4.  Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Authors:  Martina Bosnar; Zeljko Kelnerić; Vesna Munić; Vesna Eraković; Michael J Parnham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance.

Authors:  Jørgen S Jensen; Catriona S Bradshaw; Sepehr N Tabrizi; Christopher K Fairley; Ryoichi Hamasuna
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

6.  Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial.

Authors:  Lisa E Manhart; Catherine W Gillespie; M Sylvan Lowens; Christine M Khosropour; Danny V Colombara; Matthew R Golden; Navneet R Hakhu; Katherine K Thomas; James P Hughes; Nicole L Jensen; Patricia A Totten
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

7.  Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women.

Authors:  Lars Falk; Martin Enger; Jørgen Skov Jensen
Journal:  J Antimicrob Chemother       Date:  2015-08-17       Impact factor: 5.790

8.  Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey.

Authors:  Kirsten Salado-Rasmussen; Jørgen Skov Jensen
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

9.  2016 European guideline on the management of non-gonococcal urethritis.

Authors:  Patrick J Horner; Karla Blee; Lars Falk; Willem van der Meijden; Harald Moi
Journal:  Int J STD AIDS       Date:  2016-05-04       Impact factor: 1.359

Review 10.  Management of Mycoplasma genitalium infections - can we hit a moving target?

Authors:  Jørgen Skov Jensen; Catriona Bradshaw
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

View more
  1 in total

1.  Azithromycin and Doxycycline Resistance Profiles of U.S. Mycoplasma genitalium Strains and Their Association with Treatment Outcomes.

Authors:  Lisa E Manhart; Patricia A Totten; Gwendolyn E Wood; Nicole L Jensen; Sabina Astete; Jørgen S Jensen; George E Kenny; Christine M Khosropour; Catherine W Gillespie
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.